Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Status:
Withdrawn
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine
Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of
hypofractionated palliative radiation therapy in the management of unresectable,
relapsed/refractory metastatic melanoma.